Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. - Wikidata - wikimedia - TriplyDB

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

http://www.wikidata.org/entity/Q33293437

about

Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer.Fatal interstitial lung disease associated with icotinib Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.Pulmonary toxicities from targeted therapies: a review.Current status of DILD in molecular targeted therapies.Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.Interstitial lung disease associated to erlotinib treatment: a case report.From nihilism to individualism: the evolution of lung cancer therapy.EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib.[Interstitial lung disease associated with lung cancer treatment].

P2860

Q34258267-A04FF5FE-D44C-487D-9F32-C483D8C3C5F8 Q34814528-BE65856E-E2B6-4931-9836-8DBB3418BE75 Q35453113-AF195826-6377-4784-93F4-213E7B00A455 Q35850480-33DA2532-04E4-4BFD-A324-2A74EAEE57D4 Q36337416-720EDA27-2560-401C-ABAB-76F564AE000B Q37181068-7FB74D14-E05A-4BD9-8F99-CFF0A3E7CB9B Q37931083-A3C0980F-0713-4EE6-8482-196024BA7CD2 Q37955066-20A734D2-3CC7-4236-A2E6-CBF0EC92B22F Q38059819-8C859F8F-7C58-4638-8697-374EDF62FA06 Q38060727-13319195-25D9-418E-982E-9E4AC4BDF5DC Q38200654-D2CE5F58-ED34-4DE7-BF3E-5CD4D181F037 Q39025910-58D7F073-55CE-4E1E-85A6-FF0D8BF99918 Q39488527-DBA9E147-B143-49E4-9E5A-5D50D9D07D3A Q46560311-6A757250-A2B9-4814-8644-4D82B534E843 Q46634851-2D8A3620-E1B8-4D7E-BDC1-65E8F515BC4A Q53146316-6A3F8124-3FD7-42AC-ACA6-CAEF05C0CE28 Q53272704-298CE605-C58E-4508-95EF-A36FEF59C0D8 Q55299188-7F202CEE-B937-498B-8ABD-25559259F5B4 Q55465401-4C25A7C6-23F0-4E27-B9EB-780235739636

P2860

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

http://www.wikidata.org/entity/Q33293437

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@ast

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@en

type

label

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@ast

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@en

prefLabel

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@ast

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@en

P1433

Q33293437-3F6DAC08-34C5-4381-81F6-AFABB3752387

P1476

Q33293437-2EADFF0E-9DC9-4935-BC3D-84979F78DC24

P2093

Q33293437-1B385F71-0EBF-42EA-B8C0-F48C58B5A193

Q33293437-5A324544-8663-4A6E-BFE9-B86F6D29D321

Q33293437-9FFF570B-5BC4-431B-AA62-10BEEC5F3265

Q33293437-CA986DAE-B94E-4282-804F-B794B7B35B1B

Q33293437-E5B34D17-EC3C-478B-9D0B-E9B9899BCA24

Q33293437-E77385E5-11E8-4FF3-973E-8DD94D7646DD

P2860

Q33293437-085D7FA7-8A44-4833-9E14-92390D389D70

Q33293437-16B3E881-3B48-453E-A7F1-4A8E602150DF

Q33293437-2330F30E-4C12-4D4E-B5AF-9ED6E44CE938

Q33293437-2AA6E08C-571A-4B4A-8234-7BD8241A3B21

Q33293437-37823C7D-DF28-48CC-A97A-1AB2CAD49576

Q33293437-38FC334A-789B-487D-B315-41150B152784

Q33293437-6264275E-B219-47C7-ABB9-3DF87B240320

Q33293437-B844237B-B3BC-4012-99BA-F0556C789C73

Q33293437-CDB3611C-27EB-4394-A5AC-B4661609720D

P2888

Q33293437-869C3444-2257-4031-B0FC-539E7DFD3407

P304

Q33293437-51DD7925-5090-46D9-A37D-55174020133F

P31

Q33293437-9214A274-52EC-4CB3-A994-254AB5E7C86B

P356

Q33293437-1575394B-BFE8-4E1B-8A44-A89395E8AD1C

P407

Q33293437-27714E98-62EF-4E3A-A128-03DF0153F793

P478

Q33293437-24EECB29-0C25-450B-86DC-2E83E013FDFF

P50

Q33293437-DE65F873-3084-4DE2-8F26-25984ED5C2C9

P577

Q33293437-995EEEC6-8DF2-4A78-A20E-3C2923769D10

P5875

Q33293437-16C81921-4C56-48BD-A030-C61C5B27584C

P6179

Q33293437-C3927FE7-EBBE-4CFF-823D-E85D76014C60

P698

Q33293437-D162E99B-2E4A-42D0-9778-986A43899E98

P932

Q33293437-B84FDEB6-96DA-431C-A1B9-56854FBF537B

P356

1471-2407-7-150

P1433

P1476

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

@en

P2093

Arnaud Scherpereel

http://www.w3.org/2001/XMLSchema#string

Demosthenes Makris

http://www.w3.org/2001/XMLSchema#string

Guillaume Colin

http://www.w3.org/2001/XMLSchema#string

Jean Jacques Lafitte

http://www.w3.org/2001/XMLSchema#string

Luc Brun

http://www.w3.org/2001/XMLSchema#string

Marie Christine Copin

http://www.w3.org/2001/XMLSchema#string

P2860

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Severe interstitial pneumonitis associated with docetaxel administration.

Interstitial pneumonia from mitomycin.

Fatal pulmonary toxicity resulting from treatment with gemcitabine.

Severe acute interstitial pneumonia and gefitinib.

Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.

FDA drug approval summary: erlotinib (Tarceva) tablets.

Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

Interstitial pneumonitis associated with ifosfamide therapy.

P2888

1471-2407-7-150

P304

150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-7-150

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Charles Marquette

P577

2007-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6155132

http://www.w3.org/2001/XMLSchema#string

P6179

1043763075

http://www.w3.org/2001/XMLSchema#string

P698

17683587

http://www.w3.org/2001/XMLSchema#string

P932

1963454

http://www.w3.org/2001/XMLSchema#string